BIBS 222
Latest Information Update: 16 Oct 2003
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim
- Class Antihypertensives
- Mechanism of Action Angiotensin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 16 Oct 2003 Discontinued for Heart failure in Germany (unspecified route)
- 16 Oct 2003 Discontinued for Hypertension in Germany (unspecified route)
- 12 Feb 2001 Profile reviewed but no significant changes made